GLUD1 and liver cancer: Here using liver cancer as a model, we uncover a GDH1-dependent glutamine metabolic remodeling upon BET inhibition, and provide a proof-of-principle for “synthetic lethality” targeting GDH1-OXPHOS metabolic axis and BET proteins for improved cancer treatment (Fig. 6j).